Non-albicans Candida species — such as Candida glabrata — can cause vulvovaginitis that does not respond adequately to standard antifungal doses or first-line agents. This situation calls for a distinct clinical approach.
This protocol applies when: the patient has non-albicans Candida vulvovaginitis (e.g. C. glabrata vaginitis) and has not responded to usual doses or first-line antimycotic therapy. Unnecessary antimycotic therapies should be avoided; alternative antifungal strategies are indicated in this setting.
For this specific situation, locally administered alternative antifungal therapy is a key consideration. The full protocol specifies which agents apply, along with the clinical decision points and sequencing — access it below.
DOI: 10.1111/myc.13248